Osimertinib-Induced Cardiomyopathy
oleh: Shruti R. Patel, MD, Sherry-Ann N. Brown, MD, PhD, Jilan E. Kubusek, PharmD, RPh, Aaron S. Mansfield, MD, Narjust Duma, MD
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2020-04-01 |
Deskripsi
Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib is reversible and occurs at a dose of 80 mg/day. (Level of Difficulty: Intermediate.)